Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer’s Disease: Synthesis of Evidence from Observational and Interventional Trials

Susan Abushakra(Framingham State University), Martin Tolar(Alzheimer's Association), Suzanne Hendrix(TetraLogic Pharmaceuticals (United States)), Adem Albayrak(Framingham State University), Anton P. Porsteinsson(University of Rochester), Susan Flint(Framingham State University), Yongxin Yu(Framingham State University), Merçé Boada(Instituto de Salud Carlos III), Jean F. Schaefer(Framingham State University), Margaret Bray(Northeastern University), Frederik Barkhof(National Hospital for Neurology and Neurosurgery), Duygu Tosun(University of California, San Francisco), Luc Bracoud(BioClinica (United States)), Jeffrey R. Petrella(Duke Medical Center), Emer McSweeney(Cambridge Cognition (United Kingdom)), Marwan N. Sabbagh(Barrow Neurological Institute), Rosalind McLaine(Framingham State University), Sharon Cohen, J. Patrick Kesslak(Framingham State University), Serge Gauthier(McGill University Health Centre), Aidan Power, Sam Dickson(TetraLogic Pharmaceuticals (United States)), David Watson(Alzheimer’s Disease Neuroimaging Initiative), P. Murali Doraiswamy(Alzheimer’s Disease Neuroimaging Initiative), Earvin Liang, Jerome Barakos(Sutter Health), John A. Hey(Framingham State University)
CNS Drugs
December 1, 2025
Cited by 2


Related Papers